About this trial
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
Patient Profile
This trial is for patients with High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)
Where’s this trial being run?
Tallaght University Hospital and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | IMvigor011 B042843 |
|---|---|
| Number: | 21-38 |
| Full Title: | A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy |
| Principal Investigator: | Prof Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | ROCHE |
| Recruitment Started: |
Global: May 2021 Ireland: December 2021 |
| Global Recruitment Target: | 495 |
|---|---|
| Ireland Recruitment Target: | 9 |